Northern Trust Corp Voyager Therapeutics, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 406,371 shares of VYGR stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
406,371
Previous 374,161 8.61%
Holding current value
$2.63 Million
Previous $2.96 Million 19.67%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$5.77 - $9.27 $185,851 - $298,586
32,210 Added 8.61%
406,371 $2.38 Million
Q2 2024

Aug 14, 2024
SELL
$7.42 - $10.54 $116,160 - $165,003
-15,655 Reduced 4.02%
374,161 $2.96 Million
Q1 2024

May 14, 2024
BUY
$7.15 - $10.84 $535,177 - $811,374
74,850 Added 23.76%
389,816 $3.63 Million
Q4 2023

Feb 13, 2024
BUY
$6.28 - $8.81 $76,584 - $107,437
12,195 Added 4.03%
314,966 $2.66 Million
Q3 2023

Nov 13, 2023
BUY
$7.55 - $11.25 $50,215 - $74,823
6,651 Added 2.25%
302,771 $2.35 Million
Q2 2023

Aug 11, 2023
BUY
$6.94 - $13.99 $1.46 Million - $2.94 Million
210,133 Added 244.38%
296,120 $3.39 Million
Q1 2023

May 15, 2023
BUY
$6.0 - $10.78 $14,274 - $25,645
2,379 Added 2.85%
85,987 $662,000
Q4 2022

Feb 13, 2023
BUY
$4.94 - $6.61 $32,643 - $43,678
6,608 Added 8.58%
83,608 $510,000
Q3 2022

Nov 14, 2022
BUY
$5.57 - $7.47 $12,209 - $16,374
2,192 Added 2.93%
77,000 $456,000
Q2 2022

Aug 12, 2022
SELL
$4.82 - $10.09 $20,779 - $43,497
-4,311 Reduced 5.45%
74,808 $442,000
Q1 2022

May 13, 2022
BUY
$2.75 - $9.44 $4,628 - $15,887
1,683 Added 2.17%
79,119 $603,000
Q4 2021

Feb 08, 2022
BUY
$2.47 - $5.55 $6,552 - $14,724
2,653 Added 3.55%
77,436 $209,000
Q3 2021

Nov 15, 2021
SELL
$2.63 - $4.12 $25,016 - $39,189
-9,512 Reduced 11.28%
74,783 $197,000
Q2 2021

Aug 13, 2021
SELL
$3.94 - $5.44 $900,924 - $1.24 Million
-228,661 Reduced 73.06%
84,295 $348,000
Q1 2021

May 12, 2021
SELL
$4.61 - $9.04 $186,571 - $365,857
-40,471 Reduced 11.45%
312,956 $1.47 Million
Q4 2020

Feb 11, 2021
SELL
$7.15 - $12.28 $61,318 - $105,313
-8,576 Reduced 2.37%
353,427 $2.53 Million
Q3 2020

Nov 16, 2020
SELL
$10.01 - $13.75 $147,507 - $202,620
-14,736 Reduced 3.91%
362,003 $3.86 Million
Q2 2020

Aug 14, 2020
BUY
$8.05 - $14.21 $261,689 - $461,938
32,508 Added 9.44%
376,739 $4.76 Million
Q1 2020

May 14, 2020
BUY
$6.8 - $14.66 $56,936 - $122,748
8,373 Added 2.49%
344,231 $3.15 Million
Q4 2019

Feb 14, 2020
SELL
$12.82 - $16.85 $2,499 - $3,285
-195 Reduced 0.06%
335,858 $4.69 Million
Q3 2019

Nov 13, 2019
BUY
$16.31 - $28.29 $654,455 - $1.14 Million
40,126 Added 13.56%
336,053 $5.78 Million
Q2 2019

Aug 13, 2019
BUY
$19.18 - $27.88 $291,056 - $423,079
15,175 Added 5.41%
295,927 $8.06 Million
Q1 2019

May 13, 2019
BUY
$8.0 - $19.66 $45,696 - $112,297
5,712 Added 2.08%
280,752 $5.37 Million
Q4 2018

Feb 12, 2019
SELL
$8.59 - $18.05 $85,427 - $179,507
-9,945 Reduced 3.49%
275,040 $2.59 Million
Q3 2018

Nov 14, 2018
BUY
$17.11 - $21.74 $300,177 - $381,406
17,544 Added 6.56%
284,985 $5.39 Million
Q2 2018

Sep 18, 2018
SELL
$16.76 - $23.92 $28,843 - $41,166
-1,721 Reduced 0.64%
267,441 $5.23 Million
Q2 2018

Aug 14, 2018
BUY
$16.76 - $23.92 $1.15 Million - $1.65 Million
68,784 Added 34.33%
269,162 $5.26 Million
Q1 2018

May 09, 2018
BUY
$16.16 - $31.31 $101,420 - $196,501
6,276 Added 3.23%
200,378 $3.77 Million
Q4 2017

Feb 14, 2018
BUY
$12.26 - $25.88 $497,829 - $1.05 Million
40,606 Added 26.45%
194,102 $3.22 Million
Q3 2017

Nov 13, 2017
BUY
$8.37 - $20.59 $1.28 Million - $3.16 Million
153,496
153,496 $3.16 Million

Others Institutions Holding VYGR

# of Institutions
130
Shares Held
34.7M
Call Options Held
39.7K
Put Options Held
34.6K
View Full List

About Voyager Therapeutics, Inc.

VYGR Quotes by TradingView
  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $250M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email